目的:观察Notchl蛋白的表达与乳腺癌患者对紫杉醇(paclitaxel,PAC)敏感性的相关性。方法:分别利用小RNA干扰技术和Notchl胞内片段抑制剂N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-phenylglycinet—butylester(DAPT)降低乳腺癌细胞系MDA—MB-231细胞中Notchl的活性,并分别用Westernblot和RT—PCR检测两种方法的抑制效果。MTT法检测经过不同浓度紫杉醇(0、1、5、10、15、20、25I.zg/mL)处理24h后,观察对照组和实验组细胞的存活情况。通过肿瘤原代细胞胶原凝胶体包埋化疗药物敏感性检测(collagengeldropletembeddedculture—drugsensitivitytest,cD—DST)观察临床病例对紫杉醇的敏感性,并用免疫组织化学方法观察紫杉醇敏感病例和非敏感病例中Notchl的表达情况。结果:MDA—MB-231细胞对紫杉醇的敏感性增强,且与对照组之间的差异具有统计学意义(P〈0.05),免疫组化的结果显示紫杉醇敏感病例Notchl经过抑制Notchl活性处理的蛋白的表达低于不敏感病例,差异有统计学意义(P〈0.01)。结论:Notchl显著影响乳腺癌患者对紫杉醇的敏感性,Notchl表达与乳腺癌紫杉醇敏感性呈负相关。
Objective: To observe the association between Notchl expression and PAC sensitivity in breast cancer cells. Methods: The siRNA interference against Notchl and endocellular Notchl inhibitor, N-[ N-( 3,5-difluorophenacetyl ) -1-alanyl ] -S-phenylg- lycine t-butyl lester ( DAPT ) were employed to down-regulate Notchl activity and the inhibitory action was detected through Western blot and RT-PCR, respectively. After 24 hours of exposure to PAC at different concentrations ( 0, 1, 5, 10, 15, 20, 25μg/mL ), the cell vi- ability of the control group and the experimental group was tested using the MTT colorimetric method, i.e., [ 3- ( 4, 5 ) -dimethylthiahi- azo ( -z-yl ) -3,5-di-phenytetrazoliumromide ] ). Immunohistochemistry ( IHC ) was used to observe the Notchl expression in PAC-sen-sitive and non-sensitive cases, and collagen gel droplet embedded culture-drug sensitivity test ( CD-DST ) was carried out to determine the sensitivity of different cases to the PAC. Results: Down-regulation of Notchl expression by Notchl siRNA interference or inhibition of Notchl activity by DAPT significantly increased the sensitivity of MDA-MB-231 cells to PAC ( P 〈 0.05 ). In the IHC study, the Notchl expression in PAC-sensitive cases was much lower than in non-sensitive cases ( P 〈 0.01 ). Conclusion: The Notchl expression significantly influences and negatively correlates with the sensitivity of breast cancer to PAC.